Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

Completed · Phase 2

Conditions studied: Major Depressive Disorder

In brief

The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.

Key facts

Study ID

NCT01234558

Run by

Naurex, Inc, an affiliate of Allergan plc

People needed

115

Starts

2011-05-01

Expected to finish

2012-07-01

Last updated by the study team

2012-09-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• diagnosis of major depressive disorder consistent with DSM-IV-TR
• current episode greater than 8 weeks in duration
• Hamilton Depression score >/- 21
• less than 25% reduction in depression during current episode assessed by ATRQ

You may not qualify if…

• Axis diagnosis of other psychiatric disorders
• Experiencing hallucinations, delusions, other psychotic symptomatology
• ECT during current episode

Where it is running

• Mulitple — Evanston, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.